The Project Orbis initiative, which provides a framework for international partner regulators to evaluate cancer drug filings concurrently or near-concurrently with the US Food and Drug Administration, led to a 135 day reduction in the regulatory submission gap in Switzerland, according to a study published in The Lancet .
The median submission gap was 33 days for oncology marketing authorization applications (MAAs) made to Swissmedic, Switzerland’s drug regulator, through...








